

Index

- ¹³C-urea breath test, 793
- 24-h intragastric pH monitoring, 1507
- 24-hour intragastric acidity, 775
- 50mg tablet-based ¹³C urea breath test, 253
- 5-ASA, 395
- 5-hydroxytryptamine, 603
- Abbasiano, V. *see* Sartori, S.
- Abdulkarim, A.S. & Murray, J.A. Review article: the diagnosis of coeliac disease, 987
- Abrahamsson, H. *see* Simrén, M.
- Abrams, G.A. *see* Hicken, B.L.
- absenteeism, 1309
- absorption, 85
- acid, 547
- acid-suppressive medications, 1503
- Adamo, S. *see* Campieri, M.
- adenocarcinoma, 665
- adjuvant therapy, 1247
- Adler, G. *see* Von Tirpitz, C.
- adverse events, 1015
- afferent neurons, 623
- Alfal, N.A. *see* Dick, A.
- Agha-Amiri, K. *see* Peitz, U.
- aging, 271, 1399
- Agnholt, J., Dahlerup, J.F., Buntzen, S., Tottrup, A., Lyhne Nielsen, S. & Lundorf, E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease, 703
- Ahmad, T. *see* Leong, R.W.L.
- Ahrens, S.P. *see* Orenstein, S.R.
- Alba, L.M. & Lindor, K. Review article: non-alcoholic fatty liver disease, 977
- Albrecht, W. *see* Wilding, I.R.
- alcohol, 683
- Alezio, A. *see* Esposito, F.
- Alizadeh-Naini, M. *see* Kaviani, M.J.
- allergy, 459
- Alsalamah, S., Burian, M., Mahr, G., Woodcock, B.G. & Geisslinger, G. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor, 489
- amoxicillin, 1229, 1283
- Andersson, T. *see* Lindberg, P.
- Andus, T., Klebl, F., Rogler, G., Bregenzer, N., Schölmerich, J. & Straub, R.H. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study, 409
- Angerson, W.J. *see* Taha, A.S.
- Annese, V. *see* Caprilli, R.
- antacids, 1171
- anti-adhesion molecules, 1435
- antibiotic-associated diarrhoea, 905
- antibiotics, 905
- antibiotics resistance, 553
- anti-H. pylori therapy, 131
- antimitochondrial antibody, 17
- antioxidants, 137
- anti-tissue transglutaminase, 1415
- antiulcer, 1171
- appropriateness of prescription, 1503
- Arakawa, T. *see* Higuchi, K.
- area under the plasma concentration–time curve (AUC), 481
- Arguedas, M.R. *see* Hicken, B.L.
- Armstrong, D. *see* Thomson, A.B.R.
- Armuzzi, A. *see* Ciccocioppo, R.
- Armuzzi, A. *see* Leong, R.W.L.
- Arnott, I.D.R., McNeill, G. & Satsangi, J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease, 1451
- Ashley, D. *see* Prince, M.I.
- Asia, 711
- aspirin, 817
- Assandri, R. *see* Brunner, M.
- Atherton, J.C. *see* Hawkey, C.J.
- Atlan, P. *see* Beaugerie, L.
- atrophy, 193
- Aumais, G., Lefebvre, M., Tremblay, C., Bitton, A., Martin, F., Giard, A., Madi, M. & Spénard, J. Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients, 93
- Austin, A. *see* Khan, Z.H.
- autoantibodies, 1
- autoantigens, 1
- autoimmune cholangiopathy, 17
- autoimmune cholangitis, 17
- autoimmune hepatitis, 1
- Axon, A.T.R. *see* Ford, A.C.
- Ayoub, A. *see* Favennec, L.
- Azagra, R. *see* Gené, E.
- azathioprine, 1, 65, 69, 173, 827, 913
- azathioprine intolerance, 503
- Babb, P. *see* Newnham, A.
- Bai, J.C. *see* Tesei, N.
- Bain, I.M. *see* Pereira, S.P.
- Ballard II, E.D. *see* Freston, J.W.
- Barbut, F. *see* Beaugerie, L.
- Bardhan, K.D. (for the European Rabeprazole Study Group) *see* Thjodleifsson, B.
- Bargiggia, S. *see* Parente, F.
- Barkun, A.N. *see* Fallone, C.A.

- Barkun, A.N. *see* Thomson, A.B.R.
 Barone, M. *see* Ierardi, E.
 Barrett's oesophagus, 379, 547
 Barth, J. *see* Ohning, G.V.
 Bartolozzi, F. *see* Patriarca, G.
 Bastie, A. *see* Collin, B.
 Batey, R. *see* Sievert, W.
 Baumgart, D.C., Wiedenmann, B. & Dignass, A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease, 1273
 Bayerdörfler, E. *see* Lauritsen, K.
 Bazzoli, F. *see* Perri, F.
 Beaugerie, L., Flahault, A., Barbut, F., Atlan, P., Lalande, V., Cousin, P., Cadilhac, M. & Petit, J.-C. (for the study group) Antibiotic-associated diarrhoea and *Clostridium difficile* in the community, 905
 Beglinger, C. *see* Heuss, L.T.
 Behr, M. *see* Fallone, C.A.
 Behrens, C. *see* Wilding, I.R.
 Bell, S.J., Halligan, S., Windsor, A.C.J., Williams, A.B., Wiesel, P. & Kamm, M.A. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging, 387
 Bell, S.J., Williams, A.B., Wiesel, P., Wilkinson, K., Cohen, R.C.G. & Kamm, M.A. The clinical course of fistulating Crohn's disease, 1145
 Bengtsson, B. *see* Edsbäcker, S.
 Bergstrand, M. *see* Edsbäcker, S.
 Bergstrand, M. *see* Lundin, P.D.P.
 Berloco, P. *see* Russo, F.
 Bernstein, C.N. *see* Ilnyckij, A.
 beta-blockers, 145
 Bhathal, P. (for the AusHep investigators) *see* Sievert, W.
 Biagini, R. *see* Zentilin, P.
 Bianchi Porro, G. *see* Parente, F.
 Bias, P. *see* Wilding, I.R.
 Bigard, M.-A. *see* Lauritsen, K.
 Bilardi, C. *see* Zentilin, P.
 bile, 547, 923
 biliary, 137
 biliary disorders, 473, 561, 923
 biliary sludge, 473
 biliary stenting, 289
 bioavailability, 93
 birth outcome, 827
 bismuth, 415
 Bitton, A. *see* Aumais, G.
 Björnsson, E.S. *see* Simrén, M.
 Blanchard, J.F. *see* Ilnyckij, A.
 blood levels, 361
 Bloomfield, R.S. & Onken, J.E. Mercaptopurine metabolite results in clinical gastroenterology practice, 69
 Blum, A.L. *see* Pantoflickova, D.
 Blum, A.L. *see* Xia, H.H.-X.
 Bochenek, W.J. *see* Metz, D.C.
 Boehm, B.O. *see* Von Tirpitz, C.
 Bohuschke, M. *see* Malfertheiner, P.
 Bolling-Sternevald, E. *see* Xia, H.H.-X.
 Bordas, J.M. *see* Pellisé, M.
 Borghini-Fuhrer, I. *see* Rutgeerts, P.
 Borody, T. *see* O'Morain, C.
 Bosschaert, M.A.R. *see* Cats, A.
 Botta, F. *see* Testa, R.
 Bouhassira, D. *see* Collin, B.
 Bouloux, P. *see* Garland, J.
 Bouvier, C. *see* Garland, J.
 Bowden, S. *see* Sievert, W.
 Bowen, B. *see* Hunt, R.H.
 Boyce, P.M. *see* Koloski, N.A.
 brain-gut axis, 43
 Bramble, M.G. *see* Prince, M.I.
 Brayley, S. *see* Dick, A.
 breath tests, 1291
 Bregenzer, N. *see* Andus, T.
 Broekaert, D. *see* Tack, J.
 Broutet, N., Tchamgoué, S., Pereira, E., Lamouliatte, H., Salamon, R. & Mégraud, F. Risk factors for failure of *Helicobacter pylori* therapy — results of an individual data analysis of 2751 patients, 99
 Brouwers, J.R.B.J. *see* Klok, R.M.
 Brummer, R.-J.M. *see* Kilkens, T.O.C.
 Brunner, M., Assandri, R., Kletter, K., Tschurlovits, M., Corrado, M.E., Villa, R., Eichler, H.G. & Müller, M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation, 395
 Brunner, M., Greinwald, R., Kletter, K., Kvaternik, H., Corrado, M.E., Eichler, H.G. & Müller, M. Gastrointestinal transit and release of 5-aminosalicylic acid from ¹⁵³Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers, 1163
 budesonide, 403
 Bueno, M.L. *see* Coelho, L.G.V.
 Buntzen, S. *see* Agnholt, J.
 Buonomo, A. *see* Patriarca, G.
 burden of illness, 1309
 Burian, M. *see* Alsalameh, S.
 Burke, D.A. *see* Prince, M.I.
 Burroughs, A.K. *see* Mela, M.
 Burton, D.D. *see* Kim, H.J.
 Buscombe, J.R. *see* Garland, J.
 Buti, M. *see* San Miguel, R.
 Buti, M., Medina, M., Casado, M.A., Wong, J.B., Fosbrook, L. & Esteban, R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C, 687
 Cabasés, J.M. *see* San Miguel, R.
 Cadau, G. *see* Viscido, A.
 Cadilhac, M. *see* Beaugerie, L.
 cagA, 421
 Callegari, P. *see* Hunt, R.H.
 Calvert, E.L. *see* Lea, R.
 Calvet, X. *see* Gené, E.
 Calvet, X. *see* Gisbert, J.P.

- Calvet, X., Quesada, M., Roselló, M., Salceda, F., Sanfeliu, I., Dalmau, B. & Gil, M. Stool antigen for the diagnosis of *Helicobacter pylori* infection in cirrhosis: comparative usefulness of three different methods, 727
- Camilleri, M. *see* Kim, H.J.
- Cammà, C. *see* Caprilli, R.
- Campieri, M., Adamo, S., Valpiani, D., D'Arienzo, A., D'Albasio, G., Pitzalis, M., Cesari, P., Casetti, T., Castiglione, G.N., Rizzello, F., Manguso, F., Varoli, G. & Gionchetti, P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study, 1471
- Campo, S.M.A. *see* Zullo, A.
- Candelli, M. *see* Ciccocioppo, R.
- Canva, V. *see* Mathurin, P.
- Caplin, M.E. *see* Garland, J.
- Caporaso, N. *see* Esposito, F.
- Caprilli, R. *see* Viscido, A.
- Caprilli, R., Cottone, M., Tonelli, F., Sturniolo, G., Castiglione, F., Annese, V., Papi, C., Viscido, A., Cammà, C., Corrao, G. & Latella, G. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial, 517
- capsules, 361
- caraway oil, 445
- carbohydrate-intake, 1007
- carcinoid, 437
- CARD15, 1465
- cardia, 665
- cardiovascular disease, 881
- Carlsson, E. *see* Lindberg, P.
- Caro, G.D.E. *see* Testa, R.
- Cartwright, A. *see* Forbes, A.
- Caruso, M.L. *see* Russo, F.
- Casado, M.A. *see* Buti, M.
- Casetti, T. *see* Campieri, M.
- Castell, D.O. *see* Vela, M.F.
- Castells, A. *see* Pellisé, M.
- Castellvi-Bel, S. *see* Pellisé, M.
- Castiglione, F. *see* Caprilli, R.
- Castiglione, G.N. *see* Campieri, M.
- Castle, M.Z.D., Silk, D.B.A. & Libby, G.W. Letter to the Editors, 1425
- Castro, L.P. *see* Coelho, L.G.V.
- Cats, A., Kuipers, E.J., Bosschaert, M.A.R., Pot, R.G.J., Vandenbroucke-Grauls, C.M.J.E. & Kusters, J.G. Effect of frequent consumption of a *Lactobacillus casei*-containing milk drink in *Helicobacter pylori*-colonized subjects, 429
- Ceccotti, P. *see* Sartori, S.
- Cereto, F., Molina, I., González, A., Del Valle, O., Esteban, R., Guardia, J. & Genescà, J. Role of immunosuppression in the development of quinolone-resistant *Escherichia coli* spontaneous bacterial peritonitis and in the mortality of *E. coli* spontaneous bacterial peritonitis, 695
- Cesari, P. *see* Campieri, M.
- Chakraborty, B. *see* Thomson, A.B.R.
- Chalmers, D.M. *see* Ford, A.C.
- Chan, A.O.O. *see* Wong, W.M.
- Chan, C.K. *see* Wong, W.M.
- Chan, C.K. *see* Xia, H.H.X.
- Chan, F.K.L. *see* You, J.H.S.
- Chang, F.-Y. *see* Luo, J.-C.
- Chapman, M.H. *see* Garland, J.
- Chaput, J.-C. *see* Mathurin, P.
- Chaussade, S. & Minić, M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation, 165
- Chayama, K. *see* Sasaki, A.
- Chen, C.-Y. *see* Luo, J.-C.
- Chen, W.H. *see* Xia, H.H.X.
- Cheng, K. *see* Lancashire, R.J.
- Cheong, E., Igali, L., Harvey, I., Mole, M., Lund, E., Johnson, I.T. & Rhodes, M. Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study, 379
- chest pain, 1115
- Cheung, K.L. *see* Wong, W.M.
- Chiarbonello, B. *see* Testa, R.
- Chiba, N. *see* Thomson, A.B.R.
- child, 85, 571
- children, 75
- Chilton, A. *see* Williams, M.P.
- Chinese, 711, 1465
- Chinese population, 1407
- Ching, J.Y.L. *see* Leong, R.W.L.
- Chiu, Y.-L. *see* Freston, J.W.
- cholangiocarcinoma, 453
- cholecystectomy, 561
- choledocholithiasis, 453
- cholelithiasis, 453, 561
- Chow, A.C. *see* Garland, J.
- Chowdhury, R.S. & Forsmark, C.E. Review article: pancreatic function testing, 733
- chronic renal insufficiency, 1283
- Chu, K.M. *see* Wong, W.M.
- Ciccocioppo, R., Candelli, M., Di Francesco, D., Ciocca, F., Taglieri, G., Armuzzi, A., Gasbarrini, G. & Gasbarrini, A. Study of liver function in healthy elderly subjects using the ^{13}C -methacetin breath test, 271
- Ciocca, F. *see* Ciccocioppo, R.
- cirrhosis, 53, 727, 1031, 1563
- Cittadini, G. *see* Testa, R.
- clarithromycin, 259, 1229, 1283, 1381, 1541
- clinical trial, 1229, 1381
- CLIP, 1563
- Clostridium difficile*, 905
- Coelho, L.G.V., Martins, G.M., Passos, M.C.F., Bueno, M.L., Sanches, B.S.F., Lopes, L.G., Miranda, C.H.D. & Castro, L.P. Once-daily, low-cost, highly effective *Helicobacter pylori* treatment to family members of gastric cancer patients, 131
- coeliac disease, 587, 987, 1415
- coffee, 595
- Collin, B., Farmachidi, J.-P., Rueegg, P., Bastie, A. & Bouhassira, D. Tegaserod, a 5-HT₄ receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects, 577

- Cohen, R.C.G. *see* Bell, S.J.
 Cole, A.T. *see* Khan, Z.H.
colitis, 1207
 Collin, P. *see* Peräaho, M.
colonic diverticulitis, 1189
colonic diverticulosis, 1189
community, 905
connective tissue disease, 217
conscious sedation, 1493
constipation, 165
consultations, 1171
controlled-release capsules, 403
 Cooper, P. *see* Lea, R.
 Corrado, M.E. *see* Brunner, M.
 Corrao, G. *see* Caprilli, R.
corticosteroids, 1, 17
cortisol, 85
cost-effectiveness, 687
cost-effectiveness analysis, 225, 785
cost-utility analysis, 1021
 Cottone, M. *see* Caprilli, R.
 Coulie, B. *see* Tack, J.
counselling, 1333
 Cousin, P. *see* Beaugier, L.
 COX, 1371
Cox-11 selective inhibitors, 321
COX-2 selective inhibitors, 489
coxibs, 1535
 Crandall, W.V. & Mackner, L.M. *Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model*, 75
 Crawley, J.A. *see* Dean, B.B.
Crohn, 1207
Crohn's colitis, 817
Crohn's disease, 65, 185, 409, 503, 517, 703, 711, 807, 913, 1039, 1273, 1371, 1435, 1451, 1459, 1465
 Cross, S. *see* Quan, C.
 Cruickshanks, P. *see* Lea, R.
 Cryer, B. *see* Scheiman, J.M.
 Cucino, C. *see* Parente, F.
 Cui, H. *see* Martinez, S.D.
 Cuomo, R. *see* Ierardi, E.
 Cuomo, R. *see* Russo, F.
curative liver resection, 1247
cyclooxygenase-2, 379
 CYP2C19, 965, 1521, 1541
cytochrome P450 CYP2C19, 259
cytokines, 703
 Czinn, S.J. *see* Orenstein, S.R.
 Dagli, U. *see* Filik, L.
 Dahlerup, J.F. *see* Ågnholt, J.
 Dahlerup, J.F. *see* Reuther, L.O.
 D'Albasio, G. *see* Campieri, M.
 Dallaire, C. *see* O'Morain, C.
 Dalmau, B. *see* Calvet, X.
 Daniels, S. *see* Thomson, A.B.R.
 D'Arienzo, A. *see* Campieri, M.
 Davis, A.J.M. *see* Gleeson, M.H.
 Day, A. *see* Terlevich, A.
 De Boer, W.A. *see* O'Morain, C.
 De Francesco, V. *see* Ierardi, E.
 De Francesco, V. *see* Russo, F.
 De Francesco, V. *see* Zullo, A.
 De Freitas, D. *see* Lauritsen, K.
 De Micheli, E. *see* Frazzoni, M.
 De Pasquale, T. *see* Patriarca, G.
 De Solom, R. *see* Sievert, W.
 De Wit, N.J. *see* Numans, M.E.
 Dean, B.B., Crawley, J.A., Schmitt, C.M., Wong, J. & Ofman, J.J.
The burden of illness of gastro-oesophageal reflux disease: impact on work productivity, 1309
decision analysis, 1021
 Deeks, J. *see* Moayyedi, P.
dehydroepiandrosterone, 409
 Deibert, P. *see* Herrlinger, K.R.
 Dejaco, C. *see* Reinisch, W.
 Del Valle, O. *see* Cereto, F.
 Delaney, B. *see* Moayyedi, P.
depression, 43
desensitisation, 459
 Devandry, S.N. *see* Orenstein, S.R.
 Devière, J. *see* Lauritsen, K.
 Dharancy, S. *see* Mathurin, P.
 DHEA, 409
 Dhumeaux, D. *see* Hézode, C.
 Di Campli, C. *see* Patriarca, G.
 Di Francesco, D. *see* Ciccocioppo, R.
 Di Leo, A. *see* Russo, F.
 Di Matteo, G. *see* Russo, F.
diabetes mellitus, 1179
diagnosis, 369, 643, 727, 793, 1049
diagnostic criteria, 643
 Dice, J.E. *see* Orenstein, S.R.
 Dick, A., Keady, S., Mohamed, F., Brayley, S., Thomson, M., Lloyd, B.W., Heuschkel, R. & Afzal, N.A. *Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK*, 571
 Dierkhising, R.A. *see* Egan, L.J.
difficult common bile duct stones, 289
 Dignass, A.U. *see* Baumgart, D.C.
 Discepolo, F. *see* Fallone, C.A.
 Disibeyaz, S. *see* Filik, L.
diverticular disease of the colon, 1189
 Dorta, G. *see* Pantolickova, D.
dosage forms, 361
 Doust, J. *see* Ioannou, G.N.
 Dowling, R.H. *see* Pereira, S.P.
 Downes, F. *see* Isbister, G.K.
 Drewe, J. *see* Heuss, L.T.
drug combinations, 403
drug interactions, 403, 1015
drug metabolism, 69

- drug resistance, 259
 drug sensitivity testing, 119
 drug therapy, 259
 drug-induced, 887
 D'Souza, D. *see* Simrén, M.
 Dulbecco, P. *see* Zentilin, P.
 duodenal ulcer, 259
 dyspepsia, 793, 835, 1171
 dyspeptic symptoms, 881

E. coli spontaneous bacterial peritonitis, 695
 Edsbäcker, S. *see* Lundin, P.D.P.
 Edsbäcker, S., Bengtsson, B., Larsson, P., Lundin, P., Nilsson, Å., Ulmius, J. & Wollmer, P. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules, 525
 Edsbäcker, S., Larsson, P. & Bergstrand, M. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole, 403
 Edwards, N. *see* Prince, M.I.
 Egan, L.J., Myhre, G.M., Mays, D.C., Dierkhising, R.A., Kammer, P.P. & Murray, J.A. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms, 1521
 Eichler, H.G. *see* Brunner, M.
 Ejderhamn, J. *see* Lundin, P.D.P.
 Eklund, S. *see* Lauritsen, K.
 elderly, 1399
 electrohydraulic lithotripsy, 289
 Ellis, C. *see* Kang, J.-Y.
 Ellis, C. *see* Kang, J.Y.
 Eloubeidi, M. *see* Hicken, B.L.
 El-Serag, H.B. *see* Graham, D.Y.
 El-Zimaity, H.M.T. *see* Graham, D.Y.
 endomysial antibodies, 1415
 endoscopy, 155, 835, 1171, 1481, 1493
 England, 665, 1189
 Enns, R.A., Gagnon, Y.M., Rioux, K.P. & Levy, A.R. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding, 225
 Enomoto, N. *see* Miwa, H.
 enteral feeding, 853
 enteral nutrition, 307
 enterochromaffin-like cells, 343
 epidemiology, 827, 1115
 epidermal growth factor, 217
 equivalency, 361
 eradication, 111, 1333
 eradication therapy, 1529
 eradication treatment, 99, 421
 ERCP, 561
 Erdmann, J. *see* Ullrich, A.
 erosive oesophagitis, 155, 353
 Escher, J.C. *see* Lundin, P.D.P.
 Escobedo, S. *see* Thomson, A.B.R.
 Eslick, G.D., Jones, M.P. & Talley, N.J. Non-cardiac chest pain: prevalence, risk factors, impact and consulting — a population-based study, 1115
 esomeprazole, 333, 481, 1381
 Espinosa, G. *see* Sans, M.
 Esposito, F., Morisco, F., Verde, V., Ritieni, A., Alezio, A., Caporaso, N. & Fogliano, V. Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects, 595
 Esteban, R. *see* Buti, M.
 Esteban, R. *see* Cereto, F.
 ethanol, 1031
 Evans, J. *see* Hunt, R.H.
 exocrine pancreatic insufficiency, 467
 extended-release clarithromycin, 131

faecal lactase 1, 467
 Faleo, D. *see* Ierardi, E.
 Faleo, D. *see* Zullo, A.
 Fallik, D. *see* Mathurin, P.
 Fallon, M.B. *see* Hicken, B.L.
 Fallone, C.A. *see* O'Morain, C.
 Fallone, C.A., Tran, S., Semret, M., Discepolo, F., Behr, M. & Barkun, A.N. *Helicobacter* DNA in bile: correlation with hepatobiliary diseases, 453
 familia aggregation, 1389
 famotidine, 1097
 Farkkila, M. *see* Kuisma, J.
 Farley, A. *see* O'Morain, C.
 Farmachidi, J.-P. *see* Coffin, B.
Fasciola hepatica, 265
 Fass, R. *see* Martinez, S.D.
 fat intake, 1007
 Favenne, L., Jave Ortiz, J., Gargala, G., Lopez Chegne, N., Ayoub, A. & Rossignol, J.F. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru, 265
 FDA, 1015
 fear of illness, 835
 Fellermann, K. *see* Herrlinger, K.R.
 Fernández-Esparrach, G. *see* Pellisé, M.
 Fett, S.L. *see* Kalantar, J.S.
 fibrinolysis, 1039
 Filik, L., Ulker, A., Dagli, U., Parlak, E., Tunc, B. & Disibeyaz, S. Letter to the Editors, 173
 Fiocca, R. *see* Thjodleifsson, B.
 Fiocca, R. *see* Zentilin, P.
 Fischer, C. *see* Herrlinger, K.R.
 Fischler, B. *see* Tack, J.
 fistulae, 1263
 Flahault, A. *see* Beaugerie, L.
 Fleig, W.E. *see* Herrlinger, K.R.
 Fleig, W.E. *see* Zipprich, A.
 Fogliano, V. *see* Esposito, F.
 Folwaczny, C. *see* Siveke, J.T.
 Fonager, K. *see* Nørgård, B.
 food, 459

- Forbes, A., Cartwright, A., Marchant, S., McIntyre, P. & Newton, M. Review article: oral, modified-release mesalazine formulations — proprietary versus generic, 1207
- Ford, A.C., Towler, R.J., Moayyedi, P., Chalmers, D.M. & Axon, A.T.R. Mycophenolate mofetil in refractory inflammatory bowel disease, 1365
- Forman, D. *see* Moayyedi, P.
- formulary*, 571
- Fornari, F. *see* Zullo, A.
- Forsmark, C.E. *see* Chowdhury, R.S.
- Fosbrook, L. *see* Buti, M.
- Francavilla, A. *see* Ierardi, E.
- Francavilla, R. *see* Ierardi, E.
- Franceschi, M. *see* Pilotto, A.
- Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole, 235
- Freeman, J.G. *see* Khan, Z.H.
- Freston, J.W., Chiu, Y.-L., Mulford, D.J. & Ballard II, E.D. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects, 361
- Fried, M. *see* Lauritsen, K.
- Fryklund, J. *see* Lindberg, P.
- Fuentes, D., Torrente, F., Keady, S., Thirupathy, K., Thomson, M.A., Walker-Smith, J.A., Murch, S.H. & Heuschkel, R.B. High-dose azathioprine in children with inflammatory bowel disease, 913
- Fujioka, T. *see* Murakami, K.
- Fujiwara, Y. *see* Higuchi, K.
- Fumagalli, A. *see* Testa, R.
- functional bowel disorders*, 623
- functional dyspepsia*, 603, 841
- functional gastrointestinal disorders*, 1021
- Fung, F.M.Y. *see* Wong, W.M.
- Funk, P. *see* May, B.
- furazolidone*, 131
- Gagnon, Y.M. *see* Enns, R.A.
- gall bladder emptying*, 445
- gallstones*, 561, 923
- Gallus, S. *see* Parente, F.
- Gambaro, C. *see* Zentilin, P.
- Garcia-Buey, L. *see* Medina, J.
- Gardner, J.D., Sloan, S., Miner Jr, P.B. & Robinson, M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor, 955
- Gardner, J.D., Sloan, S., Miner Jr, P.B. & Robinson, M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease, 945
- Garewal, H.S. *see* Martinez, S.D.
- Gargala, G. *see* Favennec, L.
- Garland, J., Buscombe, J.R., Bouvier, C., Bouloux, P., Chapman, M.H., Chow, A.C., Reynolds, N. & Caplin, M.E. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience, 437
- Gasbarrini, A. *see* Ciccocioppo, R.
- Gasbarrini, G. *see* Ciccocioppo, R.
- Gasbarrini, G. *see* Patriarca, G.
- gastric accommodation*, 603
- gastric acid secretion*, 1109
- gastric barostat*, 603
- gastric emptying*, 445
- gastric pH*, 353, 945, 955
- gastric ulcer*, 111, 1125
- gastrins*, 343
- gastritis*, 193, 429, 547
- gastrocolonic response*, 279
- gastrointestinal*, 85, 1179
- gastrointestinal bleeding*, 225
- gastrointestinal drugs*, 361
- gastrointestinal neoplasms*, 655
- gastrointestinal neurotransmitters*, 623
- gastrointestinal oncology*, 1299
- gastrointestinal transit*, 1163
- gastro-oesophageal reflux*, 343, 1097
- gastro-oesophageal reflux disease*, 369, 785, 1057, 1171, 1309, 1407
- gastroprotection*, 321
- Gatta, L. *see* Zullo, A.
- Gatta, L., Vakil, N., Ricci, C., Osborn, J.F., Tampieri, A., Perna, F., Miglioli, M. & Vaira, D. A rapid, low-dose, ¹³C-urea tablet for the detection of *Helicobacter pylori* infection before and after treatment, 793
- Gatz, G. *see* Mallertheiner, P.
- Geisslinger, G. *see* Alsalameh, S.
- Gené, E., Calvet, X., Azagra, R. & Gisbert, J.P. Triple vs. quadruple therapy for treating *Helicobacter pylori* infection: a meta-analysis, 1137
- gender*, 75
- general practice*, 905
- Genescà, J. *see* Cereto, F.
- genetic polymorphism*, 65
- genetics*, 1465
- genotype*, 1197
- genotype distribution*, 65
- Gentile, M. *see* Ierardi, E.
- GERD, 955, 1049, 1097, 1553
- Giannini, E. *see* Testa, R.
- Giard, A. *see* Aumais, G.
- Gil, M. *see* Calvet, X.
- Giles, N. *see* Quan, C.
- Ginès, A. *see* Pellisé, M.
- Gionchetti, P. *see* Campieri, M.
- Giorgio, P. *see* Russo, F.
- Gisbert, J.P. *see* Gené, E.
- Gisbert, J.P., Jones, E.A., Pajares, J.M. & Moreno-Otero, R. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? 17
- Gisbert, J.P., Khorrami, S., Calvet, X. & Pajares, J.M. Systematic review: rabeprazole-based therapies in *Helicobacter pylori* eradication, 751

- Gladman, L.M. & Gorard, D.A. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. 651
- Gleeson, M.H. & Davis, A.J.M. Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. 817
- glucocorticosteroids, 85
- glutathione, 595
- gluten-free diet, 587
- Günther, T. *see* Peitz, U.
- Goedkoop, R. *see* Rutgeerts, P.
- Goerg, K.J. & Spilker, Th. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and oro-caecal transit time. 445
- Goh, J. & O'Morain, C.A. Review article: nutrition and adult inflammatory bowel disease. 307
- Goldfarb, N. *see* Lewis, B.
- Gomez, J.C. *see* Tesei, N.
- Gonsalkorale, W.M. *see* Lea, R.
- González, A. *see* Cereto, F.
- Gorard, D.A. *see* Gladman, L.M.
- Graeme-Cook, F. *see* Sandborn, W.J.
- Graff, L.A. *see* Ilnyckij, A.
- Graham, D.Y., Hammoud, F., El-Zimaity, H.M.T., Kim, J.G., Osato, M.S. & El-Serag, H.B. Meta-analysis: proton pump inhibitor or H₂-receptor antagonist for *Helicobacter pylori* eradication. 1229
- Graham, D.Y., Opekun, A.R., Yamaoka, Y., Osato, M.S. & El-Zimaity, H.M.T. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. 193
- Greco, S. *see* Parente, F.
- Greenon, J.K. *see* Scheiman, J.M.
- Greinwald, R. *see* Brunner, M.
- Greinwald, R. *see* Herrlinger, K.R.
- Grisendi, A. *see* Frazzoni, M.
- growth/development/nutrition, 913
- Gu, Q. *see* Wong, W.M.
- Guardia, J. *see* Cereto, F.
- Guillén-Grima, F. *see* San Miguel, R.
- Guttner, Y., Windsor, H.M., Viiala, C.H. & Marshall, B.J. Human recombinant lactoferrin is ineffective in the treatment of human *Helicobacter pylori* infection. 125
- H. pylori*, 111, 421, 453, 1065, 1237, 1283, 1535
- H. pylori* infection, 353
- H₂-receptor antagonist, 1229
- Habib, F.I. *see* Viscido, A.
- Habu, Y. *see* Kawabata, H.
- Halligan, S. *see* Bell, S.J.
- Hamada, S. *see* Kawamura, M.
- Hammer, J. *see* Quan, C.
- Hammoud, F. *see* Graham, D.Y.
- Hanauer, S.B. *see* Sandborn, W.J.
- Harnish, M.J. *see* Orr, W.C.
- Harper, S. *see* Hunt, R.H.
- Harrer, M. *see* Reinisch, W.
- Harris, A. *see* Moayyedi, P.
- Haruma, K.E.N. *see* Sasaki, A.
- Harvey, I. *see* Cheong, E.
- Hashemi, M.R. *see* Kaviani, M.J.
- Hasler, W.L. & Schoenfeld, P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. 997
- Hassan, C. *see* Zullo, A.
- Hawkey, C.J., Atherton, J.C., Treichel, H.C., Thjodleifsson, B. & Ravic, M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of *Helicobacter pylori* in patients with documented peptic ulcer disease. 1065
- Hayakumo, T. *see* Kawabata, H.
- HCC, 1563
- health care seeking, 841
- health care seeking behaviour, 1115
- health care use, 643
- Hearing, S.D. *see* Terlevich, A.
- Helicobacter, 1381
- Helicobacter pylori*, 99, 119, 125, 193, 217, 253, 259, 415, 429, 553, 727, 751, 775, 793, 965, 1057, 1075, 1137, 1229, 1333, 1345, 1529
- Helicobacter pylori* eradication, 1125
- hepatitis C, 687, 765
- hepatocellular carcinoma, 1247
- Herrlinger, K.R., Deibert, P., Schwab, M., Kreisel, W., Fischer, C., Fellermann, K. & Stange, E.F. Remission maintenance by tioguanine in chronic active Crohn's disease. 1459
- Herrlinger, K.R., Kreisel, W., Schwab, M., Schoelmerich, J., Fleig, W.E., Ruhl, A., Reinshagen, M., Fellermann, K., Greinwald, R. & Stange, E.F. 6-Thioguanine — efficacy and safety in chronic active Crohn's disease. 503
- Heuschkel, R. *see* Dick, A.
- Heuschkel, R.B. *see* Fuentes, D.
- Heuss, L.T., Schnieper, P., Drewe, J., Plimlin, E. & Beglinger, C. Conscious sedation with propofol in elderly patients: a prospective evaluation. 1493
- Högberg, L. *see* Lundin, P.D.P.
- Hicken, B.L., Sharara, A.I., Abrams, G.A., Eloubeidi, M., Fallon, M.B. & Arguedas, M.R. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. 145
- Higuchi, K., Fujiwara, Y., Tominaga, K., Watanabe, T., Shiba, M., Nakamura, S., Oshitani, N., Matsumoto, T. & Arakawa, T. Is eradication sufficient to heal gastric ulcers in patients infected with *Helicobacter pylori*? A randomized, controlled, prospective study. 111
- histamine-2 receptor antagonist, 1097
- Hoare, J. *see* Kang, J.-Y.
- Hoare, J. *see* Kang, J.Y.
- Hofbauer, L.C. *see* Von Tirpitz, C.
- Hojo, M. *see* Miwa, H.
- Holbrook, I.B. *see* Sonwalkar, S.A.
- Holt, M. *see* Khan, Z.H.
- homocysteine, 595
- Hong Kong, 711
- Honig, A. *see* Kilken, T.O.C.
- hormones and receptors, 279

- Horowitz, M. *see* Quan, C.
 hospital admissions, 1189
 hospital setting, 1503
 Houghton, L.A. *see* Lea, R.
 Hu, W.H.C. *see* Lai, K.C.
 Hu, W.H.C. *see* Wong, W.M.
 Hu, W.H.C. *see* Xia, H.H.X.
 Huang, A.-H. *see* Sheu, B.-S.
 Huang, J.-J. *see* Sheu, B.-S.
 Huang, J.Q. *see* Wong, W.M.
 Hui, C.-K., Lai, K.-C., Ng, M., Wong, W.-M., Yuen, M.-F., Lam, S.-K., Lai, C.-L. & Wong, B.C.Y. Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy, 289
 Hui, W.M. *see* Lai, K.C.
 Hui, W.M. *see* Wong, W.M.
 Hui, W.M. *see* Xia, H.H.X.
 human, 395
 Humphries, M. *see* O'Leary, C.
 Humphries, T.J. *see* Thjodleifsson, B.
 Hungin, A.P.S., Whorwell, P.J., Tack, J. & Mearin, F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects, 643
 Hunt, R.H., Harper, S., Callegari, P., Yu, C., Quan, H., Evans, J., James, C., Bowen, B. & Rashid, F. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib, 201
 Huskic, S.S. *see* Koloski, N.A.
 hypnotherapy, 635
 hypophosphataemia, 1325
 Hézode, C., Lonjon, I., Roudot-Thoraval, F., Pawlotsky, J.-M., Zafrani, E.-S. & Dhumeaux, D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study, 1031
 ibandronate, 807
 IBD, 85, 913, 1273
 iceA, 421
 idiopathic pancreatitis, 473
 Ierardi, E. *see* Russo, F.
 Ierardi, E. *see* Zullo, A.
 Ierardi, E., Muscatiello, N., Nacchiero, M., Gentile, M., Margiotta, M., Marangi, S., De Francesco, V., Francavilla, R., Barone, M., Faleo, D., Panella, C., Francavilla, A. & Cuomo, R. Second harmonic imaging improves trans-abdominal ultrasound detection of biliary sludge in 'idiopathic' pancreatitis, 473
 Igali, L. *see* Cheong, E.
 Iijima, K. *see* Kawamura, M.
 Iiritano, E. *see* Zentilin, P.
 ileo-pouch anal anastomosis (IPAA), 1263
 Ilnyckij, A., Graff, L.A., Blanchard, J.F. & Bernstein, C.N. Therapeutic value of a gastroenterology consultation in irritable bowel syndrome, 871
 immunochromatography, 1345
 immunopathogenesis, 1
 immunosuppressants, 1, 1273
 immunosuppression, 75, 695
 immunosuppressive therapy, 17
 incidence, 561, 655, 665
 induction dosing, 1197
 infant, 1097
 inflammatory bowel disease, 69, 307, 503, 711, 817, 827, 923, 1207, 1273, 1365, 1435, 1465
 inflammatory bowel disease questionnaire, 711
 inflammatory disorders, 173, 517, 1039, 1355
 infliximab, 75, 703, 1263, 1435, 1451
 infusion reactions, 75
 injection therapy, 211
 Innes, M. *see* Moayyedi, P.
 Inokuchi, H. *see* Kawabata, H.
 integrated acidity, 955
 integrins, 1435
 interferon, 611, 765, 1197
 interleukins, 193
 international, 643
 intestinal disorders, 173, 279, 517, 807, 913, 923, 1039, 1189, 1291, 1389, 1415
 intestinal infection, 905
 intraepithelial lymphocytes, 587
 intrahepatic cholestasis of pregnancy, 857
 Ioannou, G.N., Doust, J. & Rockey, D.C. Systematic review: terlipressin in acute oesophageal variceal haemorrhage, 53
 Ip, W.Y. *see* Lai, K.C.
 irritable bowel syndrome, 43, 279, 623, 635, 643, 841, 997, 1021, 1389
 Isaacs, K.L. *see* Sandborn, W.J.
 Isbister, G.K., Downes, F. & Whyte, I.M. Letter to the Editors, 609
 James, C. *see* Hunt, R.H.
 James, O.F.W. *see* Prince, M.I.
 Jansen, J.B.M.J. *see* Laheij, R.J.F.
 Janssens, J. *see* Tack, J.
 Jarvinen, H. *see* Kuisma, J.
 Jaspersen, D., Kulig, M., Labenz, J., Leodolter, A., Lind, T., Meyer-Sabellek, W., Vieth, M., Willich, S.N., Lindner, D., Stolte, M. & Malfertheiner, P. Prevalence of extraesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study, 1515
 Jave Ortiz, J. *see* Favenne, L.
 Jewell, D.P. *see* Leong, R.W.L.
 Johnson, I.T. *see* Cheong, E.
 Jones, D.E.J. *see* Prince, M.I.
 Jones, E.A. *see* Gisbert, J.P.
 Jones, M. *see* Quan, C.
 Jones, M.P. *see* Eslick, G.D.
 Jornod, P. *see* Pantoflickova, D.
 Kabir, S. Review article: clinic-based testing for *Helicobacter pylori* infection by enzyme immunoassay of faeces, urine and saliva, 1345
 Kagawa, J. *see* Murakami, K.
 Kahl, S. *see* Peitz, U.
 Kahri, A. *see* Kuisma, J.

- Kalantar, J.S., Locke III, G.R., Talley, N.J., Zinsmeister, A.R., Fett, S.L. & Melton III, L.J. Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points, 1389
- Kamm, M.A. *see* Bell, S.J.
- Kammer, P.P. *see* Egan, L.J.
- Kang, J.Y. *see* Newnham, A.
- Kang, J.-Y., Ellis, C., Majeed, A., Hoare, J., Tinto, A., Williamson, R.C.N., Tibbs, C.J. & Maxwell, J.D. Gallstones — an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000, 561
- Kang, J.Y., Hoare, J., Tinto, A., Subramanian, S., Ellis, C., Majeed, A., Melville, D. & Maxwell, J.D. Diverticular disease of the colon — on the rise: a study of hospital admissions in England between 1989/1990 and 1999/2000, 1189
- Katz, J. *see* Sandborn, W.J.
- Katz, P.O. *see* Vela, M.F.
- Katz, S. *see* Sandborn, W.J.
- Kaukinen, K. *see* Peräaho, M.
- Kaviani, M.J., Hashemi, M.R., Kazemifar, A.R., Roozitalab, S., Mostaghni, A.-A., Merat, S., Alizadeh-Naini, M. & Yarmohammadi, H. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial, 211
- Kawabata, H., Habu, Y., Tomioka, H., Kutsumi, H., Kobayashi, M., Oyasu, K., Hayakumo, T., Mizuno, S., Kiyota, K., Nakajima, M., Kimoto, K., Inokuchi, H. & Kawai, K. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of *Helicobacter pylori* infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin, 259
- Kawai, K. *see* Kawabata, H.
- Kawamura, M., Ohara, S., Koike, T., Iijima, K., Suzuki, J., Kayaba, S., Noguchi, K., Hamada, S., Noguchi, M. & Shimosegawa, T. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism, 965
- Kayaba, S. *see* Kawamura, M.
- Kazemifar, A.R. *see* Kaviani, M.J.
- Keady, S. *see* Dick, A.
- Keady, S. *see* Fuentes, D.
- Keeling, D. *see* Lindberg, P.
- Kelly, S.M. *see* Sonwalkar, S.A.
- Khan, Z.H., Simpson, E.J., Cole, A.T., Holt, M., MacDonald, I., Pye, D., Austin, A. & Freeman, J.G. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass, 677
- Khorrami, S. *see* Gisbert, J.P.
- Kilkens, T.O.C., Honig, A., Rozendaal, N., Van Nieuwenhoven, M.A. & Brummer, R.-J.M. Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome — influence on psychiatric and gastrointestinal symptoms, 43
- Kim, H.J., Camilleri, M., McKinzie, S., Lempke, M.B., Burton, D.D., Thomforde, G.M. & Zinsmeister, A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, 895
- Kim, J.G. *see* Graham, D.Y.
- Kimoto, K. *see* Kawabata, H.
- Kirchner, T. *see* Malfertheiner, P.
- Kirzin, S. *see* Mathurin, P.
- Kist, M. *see* Malfertheiner, P.
- Kiyota, K. *see* Kawabata, H.
- Klaus, J. *see* Von Tirpitz, C.
- Kleber, G. *see* Zipprich, A.
- Klebl, F. *see* Andus, T.
- Kletter, K. *see* Brunner, M.
- Klok, R.M., Postma, M.J., Van Hout, B.A. & Brouwers, J.R.B.J. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use, 1237
- Kobayashi, M. *see* Kawabata, H.
- Kodama, M. *see* Murakami, K.
- Koelz, H.R. *see* Labenz, J.
- Kohn, A. *see* Viscido, A.
- Koike, T. *see* Kawamura, M.
- Koloski, N.A., Talley, N.J., Huskic, S.S. & Boyce, P.M. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia, 841
- Kovacs, T.O.G. *see* Ohning, G.V.
- Krabbe, P.F.M. *see* Laheij, R.J.F.
- Kratzer, W. *see* Von Tirpitz, C.
- Kreisel, W. *see* Herrlinger, K.R.
- Kristjánsdóttir, S. *see* Lauritsen, K.
- Kuipers, E.J. *see* Cats, A.
- Kuisma, J., Mentula, S., Jarvinen, H., Kahri, A., Saxelin, M. & Farkkila, M. Effect of *Lactobacillus rhamnosus* GG on ileal pouch inflammation and microbial flora, 509
- Kulig, M. *see* Jaspersen, D.
- Kumar, D. *see* Pereira, S.P.
- Kurosawa, A. *see* Miwa, H.
- Kusters, J.G. *see* Cats, A.
- Kutsumi, H. *see* Kawabata, H.
- Kvaternik, H. *see* Brunner, M.
- Labenz, J. *see* Jaspersen, D.
- Labenz, J., Petersen, K.U., Rösch, W. & Koelz, H.R. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole, 1015
- lactic acid*, 429
- Lactobacillus casei*, 429
- lactoferrin*, 125
- Ladabaum, U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications, 1021
- Laheij, R.J.F., Van Rossum, L.G.M., Krabbe, P.F.M., Jansen, J.B.M.J. & Verheugt, F.W.A. The impact of gastrointestinal symptoms on health status in patients with cardiovascular disease, 881
- Lai, C.-L. *see* Hui, C.-K.
- Lai, K.-C. *see* Hui, C.-K.
- Lai, K.C. *see* Wong, W.M.
- Lai, K.C. *see* Xia, H.H.X.

- Lai, K.C., Lau, C.S., Ip, W.Y., Wong, B.C.Y., Hui, W.M., Hu, W.H.C., Wong, R.W.M. & Lam, S.K. Effect of treatment of *Helicobacter pylori* on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial, 799
- Lalande, V. *see* Beaugier, L.
- Lam, C.L.K. *see* Wong, W.M.
- Lam, K.F. *see* Wong, W.M.
- Lam, S.-K. *see* Hui, C.-K.
- Lam, S.K. *see* Lai, K.C.
- Lam, S.K. *see* Wong, W.M.
- Lam, S.K. *see* Xia, H.H.X.
- Lamouliatte, H. *see* Broutet, N.
- Lamouliatte, H. *see* Mégraud, F.
- Lancashire, R.J., Cheng, K. & Langman, M.J.S. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis, 887
- Lane, S. *see* Micklewright, R.
- Langman, M.J.S. *see* Lancashire, R.J.
- lansoprazole, 111, 235, 333, 361, 369, 775, 965, 1015, 1283, 1507
- lanzoprazole, 131
- Larder, S. *see* Lea, R.
- Larkö, A. *see* Lauritsen, K.
- Larsen, N. *see* Reuther, L.O.
- Larsson, P. *see* Edsbäcker, S.
- Latella, G. *see* Caprilli, R.
- Lau, C.P. *see* Xia, H.H.X.
- Lau, C.S. *see* Lai, K.C.
- Lauritsen, K., Devière, J., Bigard, M.-A., Bayerdörffer, E., Mózsik, G., Murray, F., Kristjánsdóttir, S., Savarino, V., Vetvik, K., De Freitas, D., Orive, V., Rodrigo, L., Fried, M., Morris, J., Schneider, H., Eklund, S. & Larkö, A. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results, 333
- laxatives*, 165
- Lea, R., Houghton, L.A., Calvert, E.L., Larder, S., Gonsalkorale, W.M., Whelan, V., Randles, J., Cooper, P., Cruickshanks, P., Miller, V. & Whorwell, P.J. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome, 635
- Leandro, G. *see* Pilotto, A.
- Lee, A.C.M. *see* You, J.H.S.
- Lee, C.S.S. Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis, 611
- Lee, J. *see* Scheiman, J.M.
- Lee, J. *see* Veldhuyzen van Zanten, S.
- Lee, S.-D. *see* Luo, J.-C.
- Lee, Y.T. *see* Leong, R.W.L.
- Lefebvre, M. *see* Aumais, G.
- Lemmens, L. *see* Rutgeerts, P.
- Lempke, M.B. *see* Kim, H.J.
- Leodolter, A. *see* Jaspersen, D.
- Leodolter, A. *see* Malfertheiner, P.
- Leodolter, A. *see* Peitz, U.
- Leong, R.W.L., Arnuzzi, A., Ahmad, T., Wong, M.L., Tse, P., Jewell, D.P. & Sung, J.J.Y. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population, 1465
- Leong, R.W.L., Lee, Y.T., Ching, J.Y.L. & Sung, J.J.Y. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire, 711
- leukopenia*, 173
- levofloxacin*, 553
- Levy, A.R. *see* Enns, R.A.
- Lewis, B. & Goldfarb, N. Review article: the advent of capsule endoscopy — a not-so-futuristic approach to obscure gastrointestinal bleeding, 1085
- Liacouras, C.A. *see* Orenstein, S.R.
- Libby, G.W. *see* Castle, M.Z.D.
- Lichtenberger, C. *see* Reinisch, W.
- Lin, H.-Y. *see* Luo, J.-C.
- Lin, S.K. *see* Wong, W.M.
- Linander, H. *see* Lundin, P.D.P.
- Lind, T. *see* Jaspersen, D.
- Lindberg, P., Keeling, D., Fryklund, J., Andersson, T., Lundborg, P. & Carlsson, E. Review article: esomeprazole — enhanced bioavailability, specificity for the proton pump and inhibition of acid secretion, 481
- Lindner, D. *see* Jaspersen, D.
- Lindor, K. *see* Alba, L.M.
- Lindquist, B. *see* Lundin, P.D.P.
- Linley, W. *see* Micklewright, R.
- liquid diet*, 307
- liver*, 1031
- liver biopsy*, 611
- liver cirrhosis*, 137, 695
- liver descriptors*, 137, 1291
- liver function*, 271
- Llach, J. *see* Pellisé, M.
- Lloyd, B.W. *see* Dick, A.
- Locke III, G.R. *see* Kalantar, J.S.
- Lohiniemi, S. *see* Peräaho, M.
- Lonjon, I. *see* Hézode, C.
- Lopes, L.G. *see* Coelho, L.G.V.
- Lopez Chegne, N. *see* Favenne, L.
- Lu, C.-L. *see* Luo, J.-C.
- Lu, R.-H. *see* Luo, J.-C.
- Lund, E. *see* Cheong, E.
- Lundborg, P. *see* Lindberg, P.
- Lundin, P. *see* Edsbäcker, S.
- Lundin, P.D.P., Edsbäcker, S., Bergstrand, M., Ejderhamn, J., Linander, H., Högberg, L., Persson, T., Escher, J.C. & Lindquist, B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease, 85
- Lundorf, E. *see* Agnholt, J.
- Luo, J.-C., Lin, H.-Y., Chang, F.-Y., Lu, R.-H., Lu, C.-L., Chen, C.-Y. & Lee, S.-D. Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia, 217
- Lyhne Nielsen, S. *see* Agnholt, J.
- McCarthy, J. *see* O'Leary, C.
- McCullagh, E. *see* Terlevich, A.
- MacDonald, I. *see* Khan, Z.H.

- McDonald, J. *see* Sievert, W.
 McIntyre, P. *see* Forbes, A.
 McKinzie, S. *see* Kim, H.J.
 McNeill, G. *see* Arnott, I.D.R.
 McQuade, C. *see* Micklewright, R.
 Machado, S. *see* Veldhuyzen van Zanten, S.
 Mackner, L.M. *see* Crandall, W.V.
 Madi, M. *see* Aumais, G.
 Mahr, G. *see* Alsalameh, S.
 Maillard reaction, 595
 maintenance therapy, 333
 Majeed, A. *see* Kang, J.-Y.
 Majeed, A. *see* Kang, J.Y.
 Majeed, A. *see* Newnham, A.
 Malagon, I.B. *see* Martinez, S.D.
 Malfatti, F. *see* Testa, R.
 Malfertheiner, P. *see* Jaspersen, D.
 Malfertheiner, P. *see* Peitz, U.
 Malfertheiner, P., Kirchner, T., Kist, M., Leodolter, A., Peitz, U., Strobel, S., Bohuschke, M., Gatz, G. & The BYK Advanced Gastric Ulcer Study (BAGUS) Group. *Helicobacter pylori* eradication and gastric ulcer healing — comparison of three pantoprazole-based triple therapies, 1125
 Manabe, N. *see* Sasaki, A.
 Mancuso, A. *see* Mela, M.
 Mandal, A., Playford, R.J. & Wicks, A.C. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK, 1319
 Manguso, F. *see* Campieri, M.
 Mansi, C. *see* Zentilin, P.
 Mar, J. *see* San Miguel, R.
 Marangi, S. *see* Ierardi, E.
 Marchant, S. *see* Forbes, A.
 Marcheggiano, A. *see* Viscido, A.
 Margiotta, M. *see* Ierardi, E.
 Margraf, J. *see* Ullrich, A.
 Marinone, G. *see* Zullo, A.
 Marinos, G. *see* Sievert, W.
 Markov model, 765
 Marshall, B.J. *see* Guttner, Y.
 Martin, F. *see* Aumais, G.
 Martinez, S.D., Malagon, I.B., Garewal, H.S., Cui, H. & Fass, R. Non-erosive reflux disease (NERD) — acid reflux and symptom patterns, 537
 Martins, G.M. *see* Coelho, L.G.V.
 Maskrey, N. *see* Micklewright, R.
 Mason, R. *see* Von Tirpitz, C.
 Mastracci, L. *see* Zentilin, P.
 Mathurin, P., Raynard, B., Dharancy, S., Kirzin, S., Fallik, D., Pruvot, F.-R., Canva, V., Paris, J.-C., Chaput, J.-C. & Naveau, S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma, 1247
 Matsumoto, T. *see* Higuchi, K.
 Mauriño, E. *see* Tesei, N.
 Maxwell, J.D. *see* Kang, J.-Y.
 Maxwell, J.D. *see* Kang, J.Y.
 May, B., Funk, P. & Schneider, B. Letter to the Editors, 975
 Mays, D.C. *see* Egan, L.J.
 Mazure, R. *see* Tesei, N.
 meal-stimulated gastric acid secretion, 945
 Mearin, F. *see* Hungin, A.P.S.
 medications, 609
 Medina, J., Garcia-Buey, L. & Moreno-Otero, R. Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis, 1
 Medina, M. *see* Buti, M.
 Meiss, F. *see* Zipprich, A.
 Mela, G.S. *see* Zentilin, P.
 Mela, M., Mancuso, A. & Burroughs, A.K. Review article: pruritus in cholestatic and other liver diseases, 857
 melanoidins, 595
 MELD, 1563
 Mele, M.R. *see* Zentilin, P.
 Melton III, L.J. *see* Kalantar, J.S.
 Melville, D. *see* Kang, J.-Y.
 Menegatti, M. *see* Zullo, A.
 Mentula, S. *see* Kuisma, J.
 Merat, S. *see* Kaviani, M.J.
 mercaptopurine, 69, 827
 Merla, A. *see* Zullo, A.
 Mertz, H. Review article: visceral hypersensitivity, 623
 mesalazine, 93, 395, 517, 1163, 1207
 meta-analysis, 751, 1137, 1229, 1237, 1247
 Mete, L.S. *see* Zullo, A.
 methacetin breath test, 271
 metronidazole, 119, 415, 1229, 1283, 1381, 1541
 Metz, D.C., Bochenek, W.J. & The Pantoprazole US GERD Study Group. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis, 155
 Meyer-Sabellek, W. *see* Jaspersen, D.
 Mégraud, F. *see* Broutet, N.
 Mégraud, F. *see* O'Morain, C.
 Mégraud, F. & Lamouliatte, H. Review article: the treatment of refractory *Helicobacter pylori* infection, 1333
 Micklewright, R., Lane, S., Linley, W., McQuade, C., Thompson, F. & Maskrey, N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors, 321
 microsomal function, 1559
 Miehsler, W. *see* Reinisch, W.
 Miglioli, M. *see* Gatta, L.
 Miglioli, M. *see* Zullo, A.
 Miller, N. *see* Thjodleifsson, B.
 Miller, V. *see* Lea, R.
 Miner Jr, P.B. *see* Gardner, J.D.
 Minić, M. *see* Chaussade, S.
 Miranda, C.H.D. *see* Coelho, L.G.V.
 Mitchell, H.M. *see* Xia, H.H.-X.
 Mitchison, H.C. *see* Prince, M.I.
 Miwa, H., Nagahara, A., Kurosawa, A., Ohkusa, T., Ohkura, R., Hojo, M., Enomoto, N. & Sato, N. Is antimicrobial susceptibility testing necessary before second-line treatment for *Helicobacter pylori* infection? 1545
 Mizuno, S. *see* Kawabata, H.
 Mäki, M. *see* Peräaho, M.

- Müller, M. *see* Brunner, M.
 Moayyedi, P. *see* Ford, A.C.
 Moayyedi, P., Soo, S., Deeks, J., Forman, D., Harris, A., Innes, M. & Delaney, B. Systematic review: antacids, H₂-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia, 1215
 Mohamed, F. *see* Dick, A.
 Mole, M. *see* Cheong, E.
 Molina, I. *see* Cereto, F.
 Mollison, L. *see* Sievert, W.
 Mora, J. *see* Pellisé, M.
 Moreno, M.L. *see* Tesei, N.
 Moreno-Otero, R. *see* Gisbert, J.P.
 Moreno-Otero, R. *see* Medina, J.
 Morini, S. *see* Zullo, A.
 Morisco, F. *see* Esposito, F.
 Morocutti, A. *see* Thjodleifsson, B.
 Morran, C.G. *see* Taha, A.S.
 Morris, J. *see* Lauritsen, K.
mortality, 655, 1189
 Mostaghni, A.-A. *see* Kaviani, M.J.
motility and nerve-gut interactions, 279, 895, 997, 1389
mucosa, 703
 Mulford, D.J. *see* Freston, J.W.
 Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M. & Kagawa, J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line *Helicobacter pylori* eradication in Japan, and the influence of metronidazole resistance, 119
 Murch, S.H. *see* Fuentes, D.
 Murray, F. *see* Lauritsen, K.
 Murray, J.A. *see* Abdulkarim, A.S.
 Murray, J.A. *see* Egan, L.J.
 Murthy, A. *see* Ohning, G.V.
 Muscatiello, N. *see* Ierardi, E.
mycophenolate mofetil, 1365
 Myhre, G.M. *see* Egan, L.J.
 Mózsik, G. *see* Lauritsen, K.

 Nacchiero, M. *see* Ierardi, E.
 Nagahara, A. *see* Miwa, H.
 Nakajima, M. *see* Kawabata, H.
 Nakamura, S. *see* Higuchi, K.
 Nasu, M. *see* Murakami, K.
natalizumab, 1435
 Navarro, S. *see* Pellisé, M.
 Naveau, S. *see* Mathurin, P.
neuroendocrine, 437
new triple therapy, 111
 Newnham, A., Quinn, M.J., Babb, P., Kang, J.Y. & Majeed, A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971–1998/1999, 655
 Newnham, A., Quinn, M.J., Babb, P., Kang, J.Y. & Majeed, A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998, 665

 Newton, M. *see* Forbes, A.
 Ng, M. *see* Hui, C.-K.
 Nielsen, I. *see* Sartori, S.
 Nilsson, Å. *see* Edsbäcker, S.
nitazoxanide, 265
 Niveloni, S. *see* Tesei, N.
nocturnal acid breakthrough, 1553
NOD2, 1465
 Noguchi, K. *see* Kawamura, M.
 Noguchi, M. *see* Kawamura, M.
 Noman, M. *see* Rutgeerts, P.
non-cardiac chest pain, 369, 1115
non-erosive reflux disease, 353
nonresponder, 1197
non-responders, 765
non-steroidal anti-inflammatory drugs, 217, 817
non-ulcer dyspepsia, 1215
 Nørgård, B., Pedersen, L., Fonager, K., Rasmussen, S.N. & Sørensen, H.T. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study, 827
 NSAID, 1371
 NSAIDs, 1535
 Nucera, E. *see* Patriarca, G.
 Numans, M.E. & De Wit, N.J. Reflux symptoms in general practice: diagnostic evaluation of the Carlsson–Dent gastro-oesophageal reflux disease questionnaire, 1049
nutrition, 307, 1007
 Nwokolo, C.U. *see* Williams, M.P.

octreotide, 53, 437
 Odenheimer, D.J. *see* Sandborn, W.J.
oesophageal adenocarcinoma, 379
oesophageal neoplasms, 655, 665
oesophageal pH, 945
oesophageal pH monitoring, 1057
oesophageal reflux, 1521
oesophageal/gastric/duodenal disorders, 1291, 1481
oesophagitis, 547, 1399
oesophagus, 1319
oesophageal pH, 955
off-label medications, 571
 Olman, J.J. *see* Dean, B.B.
 Ohara, S. *see* Kawamura, M.
 Ohkura, R. *see* Miwa, H.
 Ohkusa, T. *see* Miwa, H.
 Ohning, G.V., Walsh, J.H., Pisegna, J.R., Murthy, A., Barth, J. & Kovacs, T.O.G. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in *Helicobacter pylori*-negative subjects, 1109
 Okimoto, T. *see* Murakami, K.
 O'Leary, C., McCarthy, J., Humphries, M., Shanahan, F. & Quigley, E. The prophylactic use of a proton pump inhibitor before food and alcohol, 683
omeprazole, 343, 403, 415, 481, 751, 775, 1015, 1049, 1065, 1381, 1507

- O'Morain, C., Borody, T., Farley, A., De Boer, W.A., Dallaire, C., Schuman, R., Piotrowski, J., Fallone, C.A., Tytgat, G., Mégraud, F. & Spénard, J. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of *Helicobacter pylori*: an international multicentre study, 415
- O'Morain, C.A. *see* Goh, J.
- O'Morain, C.A. *see* Xia, H.H.-X.
- oncercept*, 185
- one-month survey*, 1503
- Onken, J.E. *see* Bloomfield, R.S.
- onset of antisecretory action*, 1507
- Opekun, A.R. *see* Graham, D.Y.
- oral omeprazole*, 211
- orally-disintegrating tablets*, 361
- Orenstein, S.R., Shalaby, T.M., Devandry, S.N., Liacouras, C.A., Czinn, S.J., Dice, J.E., Simon, T.J., Ahrens, S.P. & Stauffer, L.A. Famotidine for infant gastro-oesophageal reflux: a multicentre, randomized, placebo-controlled, withdrawal trial, 1097
- Orive, V. *see* Lauritsen, K.
- orlistat*, 1007
- orocaecal transit time*, 445
- Orr, W.C. & Harnish, M.J. The efficacy of omeprazole twice daily with supplemental H₂ blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity, 1553
- Osato, M.S. *see* Graham, D.Y.
- Osborn, J.F. *see* Gatta, L.
- Oshitani, N. *see* Higuchi, K.
- osteoporosis*, 307, 807
- overdose*, 609
- Oyasu, K. *see* Kawabata, H.
- Paasikivi, K. *see* Peräaho, M.
- PABA test*, 467
- paediatric gastroenterology*, 571
- paediatrics*, 571
- Pajares, J.M. *see* Gisbert, J.P.
- pancreatic disorders*, 1291, 1299
- pancreatitis*, 887
- Pandolfo, N. *see* Zentilin, P.
- Panella, C. *see* Ierardi, E.
- Panés, J. *see* Sans, M.
- Pantoflickova, D., Dorta, G., Ravic, M., Jornod, P. & Blum, A.L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors, 1507
- pantoprazole*, 155, 235, 1015, 1125, 1399, 1507
- Papadia, C. *see* Zullo, A.
- Papi, C. *see* Caprilli, R.
- Papi, C. *see* Viscido, A.
- paracetamol*, 609
- Parenate, F., Cucino, C., Gallus, S., Bargiggia, S., Greco, S., Pastore, L. & Bianchi Porro, G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey, 1503
- Paris, J.-C. *see* Mathurin, P.
- Parlak, E. *see* Filik, L.
- paroxetine*, 603
- Passos, M.C.F. *see* Coelho, L.G.V.
- Pastore, L. *see* Parente, F.
- pathogens*, 905
- Patriarca, G., Nucera, E., Roncallo, C., Pollastrini, E., Bartolozzi, F., De Pasquale, T., Buonomo, A., Gasbarrini, G., Di Campli, C. & Schiavino, D. Oral desensitizing treatment in food allergy: clinical and immunological results, 459
- Pawlotsky, J.-M. *see* Hézode, C.
- Pedersen, L. *see* Nørgård, B.
- PEG 3350*, 165
- PEG 4000*, 165
- peginterferon alfa-2b*, 687
- pegylated interferon*, 611
- Peitz, U. *see* Malfertheiner, P.
- Peitz, U., Leodolter, A., Kahl, S., Agha-Amiri, K., Wex, T., Wolle, K., Günther, T., Steinbrink, B. & Malfertheiner, P. Antigen stool test for assessment of *Helicobacter pylori* infection in patients with upper gastrointestinal bleeding, 1075
- pellets*, 1163
- Pellisè, M. *see* Sans, M.
- Pellisè, M., Castells, A., Ginès, A., Solé, M., Mora, J., Castellvi-Bel, S., Rodríguez-Moranta, F., Fernández-Esparrach, G., Llach, J., Borda, J.M., Navarro, S. & Piqué, J.M. Clinical usefulness of KRAS mutational analysis in the diagnosis of pancreatic adenocarcinoma by means of endosonography-guided fine-needle aspiration biopsy, 1299
- peppermint oil*, 445
- peptic ulcer*, 259, 1075, 1237
- peptic ulcer disease*, 211, 217, 225
- Peräaho, M., Kaukinen, K., Paasikivi, K., Sievänen, H., Lohiniemi, S., Mäki, M. & Collin, P. Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study, 587
- percutaneous endoscopic gastrostomy*, 533
- Pereira, E. *see* Broutet, N.
- Pereira, S.P., Bain, I.M., Kumar, D. & Dowling, R.H. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile, 923
- Perna, F. *see* Gatta, L.
- Perna, F. *see* Zullo, A.
- Perri, F. *see* Zullo, A.
- Perri, F., Zagari, R.M., Uebersax, J.S., Quitadamo, M., Bazzoli, F. & The *Helicobacter Pylori* SIGE Study Group on ¹³CO₂ Measurement Standardization. An inter- and intra-laboratory comparison of breath ¹³CO₂ analysis, 1291
- Persson, T. *see* Lundin, P.D.P.
- Peru*, 265
- Petersen, K.U. *see* Labenz, J.
- Petit, J.-C. (*for the study group*), *see* Beaugier, L.
- Pflimlin, E. *see* Heuss, L.T.
- pharmacogenetics*, 1521
- pharmacokinetics*, 85, 361, 395, 403
- pharmacoscintigraphy*, 395, 1163
- phenolic compounds*, 595
- Phillips, I. *see* Sonwalkar, S.A.

- Phosphates Polyfusor, 1325
 phytopharmakon, 445
 Pianko, S. *see* Sievert, W.
 Pilati, S. *see* Zullo, A.
 pilot study, 185
 Pilotto, A., Leandro, G., Franceschi, M. & (on behalf of the Ageing, Acid-Related Disease Study Group). Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole, 1399
 Pimpo, M.T. *see* Viscido, A.
 Piotrowski, J. *see* O'Morain, C.
 Piqué, J.M. *see* Pellisé, M.
 Piqué, J.M. *see* Sans, M.
 Pisegna, J.R. *see* Ohning, G.V.
 Pitzalis, M. *see* Campieri, M.
 plasma gastrin, 775
 Playford, R.J. *see* Mandal, A.
 Podesta, E. *see* Testa, R.
 poisoning, 609
 Polegato, S. *see* Testa, R.
 Pollastrini, E. *see* Patriarca, G.
 polyethylene glycol, 165
 polyurethane, 853
 population-based, 1115
 portal hypertension, 53
 portal venous pressure gradient, 145
 Postma, M.J. *see* Klok, R.M.
 postoperative recurrence, 517
 Poti, R. *see* Zullo, A.
 Pot, R.G.J. *see* Cats, A.
 pouchitis, 1263, 1273
 Pounder, R.E. *see* Williams, M.P.
 PPI, 1015, 1065
 PPI/AC, 1541
 predictability, 611
 predicting response, 1451
 Present, D.H. *see* Sandborn, W.J.
 prevalence, 643, 1481
 prevention, 517
 primary biliary cirrhosis, 17, 857
 primary care, 1481
 primary sclerosing cholangitis, 453
 Prince, M.I., Mitchison, H.C., Ashley, D., Burke, D.A., Edwards, N., Bramble, M.G., James, O.F.W. & Jones, D.E.J. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial, 137
 Probert, C.S.J. *see* Terlevich, A.
 probiotics, 429
 proctitis, 93
 propofol, 1493
 prostaglandins, 1535
 proton pump inhibitor, 225, 481, 683, 751, 785, 1109, 1229, 1237, 1521
 provocative meal, 683
 pruritis, 857
 Pruvot, F.-R. *see* Mathurin, P.
 psychological factors, 1115
 Pye, D. *see* Khan, Z.H.
 Quadri, A. & Vakil, N. Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia, 835
 quadruple, 553, 1137
 quadruple therapy, 1333
 qualitative analysis, 43
 quality of life, 711, 881, 1021, 1115
 Quan, C., Talley, N.J., Cross, S., Jones, M., Hammer, J., Giles, N. & Horowitz, M. Development and validation of the Diabetes Bowel Symptom Questionnaire, 1179
 Quan, H. *see* Hunt, R.H.
 Quesada, M. *see* Calvet, X.
 questionnaire, 711, 1049, 1179, 1407
 Quigley, E. *see* O'Leary, C.
 Quinn, M.J. *see* Newnham, A.
 quinolone resistance, 695
 Quintó, L. *see* Sans, M.
 Quitadamo, M. *see* Perri, F.
 rabeprazole, 111, 119, 259, 343, 553, 751, 775, 1065, 1109, 1507
 Randles, J. *see* Lea, R.
 randomised controlled trial, 259, 343
 Rashid, F. *see* Hunt, R.H.
 Rasmussen, S.N. *see* Nørgård, B.
 Ravic, M. *see* Hawkey, C.J.
 Ravic, M. *see* Pantolickova, D.
 Raynard, B. *see* Mathurin, P.
 reassurance, 835
 rectal distension, 577
 rectal sensitivity, 577, 635
 recurrent acute cholangitis, 289
 Reed, W. *see* Sievert, W.
 refeeding syndrome, 1325
 reflux, 235, 683
 reflux disease, 1237
 reflux oesophagitis, 333, 965, 1529
 Reglioni, S. *see* Zentilin, P.
 Reid, D. *see* Terlevich, A.
 Reinisch, W., Miehsler, W., Dejaco, C., Harrer, M., Waldhoer, T., Lichtenberger, C. & Vogelsang, H. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia, 1371
 Reinshagen, M. *see* Herrlinger, K.R.
 Reinshagen, M. *see* Von Tirpitz, C.
 relapse, 155
 remission maintenance, 1459
 repifermin, 1355
 rescue therapy, 1273
 resistance, 1125
 response, 703

- Reuther, L.O., Sonne, J., Larsen, N., Dahlerup, J.F., Thomsen, O.O. & Schmiegelow, K. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease, 65
- Reverter, J.C. *see* Sans, M.
- review, 43
- Reynolds, N. *see* Garland, J.
- Rhodes, M. *see* Cheong, E.
- ribavirin, 611, 687, 765, 1197
- Ricci, C. *see* Gatta, L.
- Ricci, C. *see* Zullo, A.
- rifabutin, 553
- Rinaldi, V. *see* Zullo, A.
- Rindi, G. *see* Thjodleifsson, B.
- Rioux, K.P. *see* Enns, R.A.
- risk factors, 99
- Risso, D. *see* Testa, R.
- Ritieni, A. *see* Esposito, F.
- Rizzello, F. *see* Campieri, M.
- Robinson, M. *see* Gardner, J.D.
- ROC curve, 1049
- Rockey, D.C. *see* Ioannou, G.N.
- Rodríguez-Moranta, F. *see* Pellisé, M.
- Rodrigo, L. *see* Lauritsen, K.
- rofecoxib, 1371
- Rogler, G. *see* Andus, T.
- Romagnoli, P. *see* Testa, R.
- Roncallo, C. *see* Patriarca, G.
- Roositalab, S. *see* Kavian, M.J.
- Roselló, M. *see* Calvet, X.
- Rosignol, J.F. *see* Favenec, L.
- Roudot-Thoraval, F. *see* Hézode, C.
- Rozendaal, N. *see* Kilkens, T.O.C.
- Rösch, W. *see* Labenz, J.
- Rueegg, P. *see* Coffin, B.
- Ruhl, A. *see* Herrlinger, K.R.
- Russo, F., Berloco, P., Cuomo, R., Caruso, M.L., Di Matteo, G., Giorgio, P., De Francesco, V., Di Leo, A. & Ierardi, E. *Helicobacter pylori* strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy, 421
- Rutgeerts, P., Lemmens, L., Van Assche, G., Noman, M., Borghini-Fuhrer, I. & Goedkoop, R. Treatment of active Crohn's disease with oncept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study, 185
- Rutgeerts, P., Van Deventer, S. & Schreiber, S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition, 1435
- Safdi, M. *see* Sandborn, W.J.
- safety, 361, 1493
- Salamon, R. *see* Broutet, N.
- Salceda, F. *see* Calvet, X.
- saliva, 217
- salivary ELISA, 1345
- San Miguel, R., Mar, J., Cabasés, J.M., Guillén-Grima, F. & Buti, M. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon, 765
- Sanches, B.S.F. *see* Coelho, L.G.V.
- Sandborn, W.J., Sands, B.E., Wolf, D.C., Valentine, J.F., Safdi, M., Katz, S., Isaacs, K.L., Wruble, L.D., Katz, J., Present, D.H., E.V.Loftus Jr., Graeme-Cook, F., Odenheimer, D.J. & Hanauer, S.B. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial, 1355
- Sandborn, W.J. & Hanauer, S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis, 29
- sandostatin LAR, 437
- Sands, B.E. *see* Sandborn, W.J.
- Sanfeliu, I. *see* Calvet, X.
- Sans, M., Tassies, D., Pellisé, M., Espinosa, G., Quintó, L., Piqué, J.M., Reverter, J.C. & Panés, J. The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease, 1039
- Sartori, S., Trevisani, L., Nielsen, L., Tassinari, D., Ceccotti, P. & Abbasciano, V. Longevity of silicone and polyurethane catheters in long-term enteral feeding via percutaneous endoscopic gastrostomy, 853
- Sasaki, A., Haruma, K.E.N., Manabe, N., Tanaka, S., Yoshihara, M. & Chayama, K. Long-term observation of reflux oesophagitis developing after *Helicobacter pylori* eradication therapy, 1529
- Sato, N. *see* Miwa, H.
- Sato, R. *see* Murakami, K.
- Satsangi, J. *see* Arnott, I.D.R.
- Savarino, V. *see* Frazzoni, M.
- Savarino, V. *see* Lauritsen, K.
- Savarino, V. *see* Zentilin, P.
- Savioli, A. *see* Zullo, A.
- Saxelin, M. *see* Kuisma, J.
- Scheiman, J.M., Greenon, J.K., Lee, J. & Cryer, B. Effect of cyclooxygenase-2 inhibition on human *Helicobacter pylori* gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention, 1535
- Schiavino, D. *see* Patriarca, G.
- Schölmerich, J. *see* Andus, T.
- Schmiegelow, K. *see* Reuther, L.O.
- Schmitt, C.M. *see* Dean, B.B.
- Schneider, B. *see* May, B.
- Schneider, H. *see* Lauritsen, K.
- Schnieper, P. *see* Heuss, L.T.
- Schoelmerich, J. *see* Herrlinger, K.R.
- Schoenfeld, P. *see* Hasler, W.L.
- Schreiber, S. *see* Rutgeerts, P.
- Schuman, R. *see* O'Morain, C.
- Schusdziarra, V. *see* Ullrich, A.
- Schwab, M. *see* Herrlinger, K.R.
- sclerotherapy, 53

- second harmonic imaging, 473
 second-line therapy, 119
 second-line treatment, 553
 Semret, M. *see* Fallone, C.A.
 Sercombe, J. *see* Williams, M.P.
 serology screening diagnosis, 1415
 serotonin, 43
 Shalaby, T.M. *see* Orenstein, S.R.
 Shanahan, F. *see* O'Leary, C.
 Sharara, A.I. *see* Hicken, B.L.
 Sharma, P. *see* Vakil, N.
 Sharma, P. & Vakil, N. Review article: *Helicobacter pylori* and reflux disease, 297
 Sheu, B.-S., Huang, J.-J., Yang, H.-B., Huang, A.-H. & Wu, J.-J. The selection of triple therapy for *Helicobacter pylori* eradication in chronic renal insufficiency, 1283
 Shiba, M. *see* Higuchi, K.
 Shimosegawa, T. *see* Kawamura, M.
 short-term triple therapy, 1125
 side effects, 1459
 Sievert, W., Batey, R., Mollison, L., Pianko, S., McDonald, J., Marinos, G., Reed, W., Warner, S., Bowden, S., De Solom, R. & Bhathal, P. (for the AusHep investigators) Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone, 1197
 Sievänen, H. *see* Peräaho, M.
 silicone, 853
 Silk, D.B.A. *see* Castle, M.Z.D.
 Simms, L. *see* Simrén, M.
 Simon, T.J. *see* Orenstein, S.R.
 Simpson, E.J. *see* Khan, Z.H.
 Simrén, M., Simms, L., D'Souza, D., Abrahamsson, H. & Björnsson, E.S. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT₃ receptors, 279
 Sinclair, P. *see* Thomson, A.B.R.
 Siveke, J.T. & Folwaczny, C. Letter to the Editors, 479
 Sloan, S. *see* Gardner, J.D.
 Smecuol, E. *see* Tesei, N.
 Smyth, C. *see* Terlevich, A.
 sodium fluoride, 807
 Solé, M. *see* Pellisé, M.
 somatostatin, 53, 437
 Sonne, J. *see* Reuther, L.O.
 Sonwalkar, S.A., Holbrook, I.B., Phillips, I. & Kelly, S.M. A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function, 467
 Soo, S. *see* Moayyedi, P.
 Spaggiari, P. *see* Zentilin, P.
 Spilker, Th. *see* Goerg, K.J.
 Spénard, J. *see* Aumais, G.
 Spénard, J. *see* O'Morain, C.
 Sorensen, H.T. *see* Norgård, B.
 stable isotope spectrometry, 1559
 stable isotopes, 1291
 Stange, E.F. *see* Herrlinger, K.R.
 Stauffer, L.A. *see* Orenstein, S.R.
 steatosis, 1031
 Steinbrink, B. *see* Peitz, U.
 Steinkamp, M. *see* Von Tirpitz, C.
 Stern, J.M. Review article: psychiatry, psychotherapy and gastroenterology — bringing it all together, 175
 steroid-dependent, 1365
 Steudel, N. *see* Zipprich, A.
 Stolte, M. *see* Jaspersen, D.
 Stolte, M. *see* Xia, H.H.-X.
 stomach neoplasms, 655, 665
 stomach ulcer, 259
 stool antigen assay, 1345
 stool test, 1075
 Straub, R.H. *see* Andus, T.
 Strobel, S. *see* Malfertheiner, P.
 Sturniolo, G. *see* Caprilli, R.
 Subramanian, S. *see* Kang, J.Y.
 Sugai, E. *see* Tesei, N.
 Sung, J.J.Y. *see* Leong, R.W.L.
 suppositories, 93
 surgery, 547, 997, 1189
 surveillance, 1319
 survival rate, 655
 susceptibility testing, 1333
 Suzuki, J. *see* Kawamura, M.
 symptoms, 1179
 systematic review, 751, 1215
 Szigoleit, U. *see* Zipprich, A.
 TACE, 1563
 Tack, J. *see* Hungin, A.P.S.
 Tack, J., Broekaert, D., Coulie, B., Fischler, B. & Janssens, J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans, 603
 tacrolimus, 1273
 Taglieri, G. *see* Cicciocioppo, R.
 Taha, A.S., Angerson, W.J. & Morran, C.G. Reflux and Barrett's oesophagus after gastric surgery — long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis, 547
 Talley, N.J. *see* Eslick, G.D.
 Talley, N.J. *see* Kalantar, J.S.
 Talley, N.J. *see* Koloski, N.A.
 Talley, N.J. *see* Quan, C.
 Talley, N.J. *see* Westbrook, J.I.
 Talley, N.J. *see* Xia, H.H.-X.
 Tampieri, A. *see* Gatta, L.
 Tampieri, A. *see* Zullo, A.
 Tanaka, S. *see* Sasaki, A.
 Tardif, S.J. *see* Wilding, I.R.
 Tassinari, D. *see* Sartori, S.
 Tchamgoué, S. *see* Broutet, N.
 tegaserod, 577
 Terlevich, A., Hearing, S.D., Woltersdorf, W.W., Smyth, C., Reid, D., McCullagh, E., Day, A. & Probert, C.S.J. Refeeding syndrome: effective and safe treatment with Phosphates Polyfusor, 1325

- Tesei, N., Sugai, E., Vázquez, H., Smecuol, E., Niveloni, S., Mazure, R., Moreno, M.L., Gomez, J.C., Mauriño, E. & Bai, J.C. Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies, 1415
- Tessieri, L. *see* Zentilin, P.
- Testa, E. *see* Testa, R.
- Testa, R., Testa, E., Giannini, E., Botta, F., Malfatti, F., Chiarbonello, B., Fumagalli, A., Polegato, S., Podesta, E., Romagnoli, P., Risso, D., Cittadini, G. & Caro, G.D.E. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems. Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment, 1563
- tetracycline, 415
- The BYK Advanced Gastric Ulcer Study (BAGUS) Group. *see* Malfertheiner, P.
- The Helicobacter Pylori SIGE Study Group on $^{13}\text{C}_2$ Measurement Standardization. *see* Perri, F.
- The Pantoprazole US GERD Study Group. *see* Metz, D.C.
- therapeutic alternatives, 1
- therapy, 409, 751
- thiopurine methyltransferase, 65
- Thirrupathy, K. *see* Fuentes, D.
- Thjodleifsson, B. *see* Hawkey, C.J.
- Thjodleifsson, B., Rindi, G., Fiocca, R., Humphries, T.J., Morocutti, A., Miller, N. & Bardhan, K.D. (for the European Rabepazole Study Group) A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabepazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years, 343
- Thomforde, G.M. *see* Kim, H.J.
- Thompson, F. *see* Micklewright, R.
- Thomsen, O.O. *see* Reuther, L.O.
- Thomson, A.B.R., Barkun, A.N., Armstrong, D., Chiba, N., White, R.J., Daniels, S., Escobedo, S., Chakraborty, B., Sinclair, P. & Veldhuyzen Van Zanten, S.J.O. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET-PE) study, 1481
- Thomson, M. *see* Dick, A.
- Thomson, M.A. *see* Fuentes, D.
- Tibbs, C.J. *see* Kang, J.-Y.
- Tinto, A. *see* Kang, J.-Y.
- Tinto, A. *see* Kang, J.Y.
- tioguanine, 503, 1459
- tissue, 93
- TNF-binding protein, 185
- Tominaga, K. *see* Higuchi, K.
- Tomioka, H. *see* Kawabata, H.
- Tonelli, F. *see* Caprilli, R.
- Torrente, F. *see* Fuentes, D.
- Towler, R.J. *see* Ford, A.C.
- toxicity, 609
- TPN, 307
- Tran, S. *see* Fallone, C.A.
- transabdominal ultrasonography, 473
- treatment, 265, 1137, 1325, 1381
- treatment failure, 99
- Treichel, H.C. *see* Hawkey, C.J.
- Tremblay, C. *see* Aumais, G.
- Trevisani, L. *see* Sartori, S.
- triple, 1137
- triple therapy, 1283
- tri-therapy, 99
- Tschurlovits, M. *see* Brunner, M.
- Tse, P. *see* Leong, R.W.L.
- Tassies, D. *see* Sans, M.
- Tottrup, A. *see* Agnholt, J.
- Tunc, B. *see* Filik, L.
- Tutuian, R. *see* Vela, M.F.
- Tytgat, G. *see* O'Morain, C.
- Uebersax, J.S. *see* Perri, F.
- ulcer, 1065
- ulcer disease, 1125
- ulcer healing, 111
- ulcerative colitis, 409, 711, 817, 1263, 1273, 1435
- Ulker, A. *see* Filik, L.
- Ulrich, A., Erdmann, J., Margraf, J. & Schusdziarra, V. Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat, 1007
- Ulmus, J. *see* Edsbäcker, S.
- uninvestigated dyspepsia, 1481
- unlicensed medications, 571
- upper gastrointestinal bleeding, 211, 1075
- urea breath test, 125
- urease activity, 429
- urinary ELISA, 1345
- ursodeoxycholic acid, 17, 857
- Usselman, B. *see* Williams, M.P.
- vacA, 421
- vagotomy, 547
- Vaira, D. *see* Gatta, L.
- Vaira, D. *see* Zullo, A.
- Vakil, N. *see* Gatta, L.
- Vakil, N. *see* Quadri, A.
- Vakil, N. *see* Sharma, P.
- Vakil, N. *see* Zullo, A.
- Vakil, N. & Sharma, P. Review article: endoscopic treatments for gastro-oesophageal reflux disease, 1427
- valdecocib, 489
- Valentine, J.F. *see* Sandborn, W.J.
- validation, 711, 1407
- Valpiani, D. *see* Campieri, M.
- Van Assche, G. *see* Rutgeerts, P.
- Van Deventer, S. *see* Rutgeerts, P.
- Van Hout, B.A. *see* Klok, R.M.
- Van Nieuwenhoven, M.A. *see* Kilkens, T.O.C.
- Van Rossum, L.G.M. *see* Laheij, R.J.F.
- Vandenbroucke-Grauls, C.M.J.E. *see* Cats, A.

- variations, 643
 variceal bleeding, 145
 Varoli, G. *see* Campieri, M.
 vasopressin, 53
 Vela, M.F., Tutuian, R., Katz, P.O. & Castell, D.O. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH, 243
 Veldhuyzen van Zanten, S., Machado, S. & Lee, J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of *Helicobacter pylori* infection, 1381
 Veldhuyzen Van Zanten, S.J.O. *see* Thomson, A.B.R.
 Verde, V. *see* Esposito, F.
 Verheugt, F.W.A. *see* Laheij, R.J.F.
 Vernia, P. *see* Viscido, A.
 Vetvik, K. *see* Lauritsen, K.
 Vieth, M. *see* Jaspersen, D.
 Vignale, C. *see* Zentilin, P.
 Vigneri, S. *see* Zentilin, P.
 Viiala, C.H. *see* Guttner, Y.
 Villa, R. *see* Brunner, M.
 viral hepatitis, 1031
 visceral hypersensitivity, 623
 Viscido, A. *see* Caprilli, R.
 Viscido, A., Habib, F.I., Kohn, A., Papi, C., Marcheggiano, A., Pimpo, M.T., Vernia, P., Cadau, G. & Caprilli, R. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis, 1263
 vitamin K antagonists, 1015
 Vogelsang, H. *see* Reinisch, W.
 Von Tirpitz, C., Klaus, J., Steinkamp, M., Hofbauer, L.C., Kratzer, W., Mason, R., Boehm, B.O., Adler, G. & Reinshagen, M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate, 807
 Vázquez, H. *see* Tesei, N.
 Waldhoer, T. *see* Reinisch, W.
 Wales, 665
 Walker-Smith, J.A. *see* Fuentes, D.
 Walsh, J.H. *see* Ohning, G.V.
 warfarin, 1015
 Warner, S. *see* Sievert, W.
 Watanabe, T. *see* Higuchi, K.
 weight loss, 1007
 Westbrook, J.I. & Talley, N.J. Diagnostic investigation rates and use of prescription and non-prescription medications amongst dyspeptics: a population-based study of 2300 Australians, 1171
 Wex, T. *see* Peitz, U.
 wheat starch, 587
 Whelan, V. *see* Lea, R.
 White, R.J. *see* Thomson, A.B.R.
 Whorwell, P.J. *see* Hungin, A.P.S.
 Whorwell, P.J. *see* Lea, R.
 Whyte, I.M. *see* Isbister, G.K.
 Wicks, A.C. *see* Mandal, A.
 Wiedenmann, B. *see* Baumgart, D.C.
 Wiesel, P. *see* Bell, S.J.
 Wilding, I.R., Behrens, C., Tardif, S.J., Wray, H., Bias, P. & Albrecht, W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects, 1153
 Wilkinson, K. *see* Bell, S.J.
 Williams, A.B. *see* Bell, S.J.
 Williams, M.P., Usselman, B., Chilton, A., Sercombe, J., Nwokolo, C.U. & Pounder, R.E. Eradication of *Helicobacter pylori* increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo, 775
 Williamson, R.C.N. *see* Kang, J.-Y.
 Willich, S.N. *see* Jaspersen, D.
 Windsor, A.C.J. *see* Bell, S.J.
 Windsor, H.M. *see* Guttner, Y.
 Wolf, D.C. *see* Sandborn, W.J.
 Wolle, K. *see* Peitz, U.
 Wollmer, P. *see* Edsbäcker, S.
 Woltersdorf, W.W. *see* Terlevich, A.
 Wong, B.C.Y. *see* Hui, C.-K.
 Wong, B.C.Y. *see* Lai, K.C.
 Wong, B.C.Y. *see* Wong, W.M.
 Wong, B.C.Y. *see* Xia, H.H.X.
 Wong, J. *see* Dean, B.B.
 Wong, J.B. *see* Buti, M.
 Wong, K.W. *see* Wong, W.M.
 Wong, M.I. *see* Leong, R.W.L.
 Wong, N.Y.H. *see* Wong, W.M.
 Wong, N.Y.H. *see* Xia, H.H.X.
 Wong, R.W.M. *see* Lai, K.C.
 Wong, S.C.Y. *see* You, J.H.S.
 Wong, W.-M. *see* Hui, C.-K.
 Wong, W.M. *see* Xia, H.H.X.
 Wong, W.M., Gu, Q., Lam, S.K., Fung, F.M.Y., Lai, K.C., Hu, W.H.C., Yee, Y.K., Chan, C.K., Xia, H.H.X., Yuen, M.F. & Wong, B.C.Y. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for *Helicobacter pylori* infection, 553
 Wong, W.M., Lam, K.F., Lai, K.C., Hui, W.M., Hu, W.H.C., Lam, C.L.K., Wong, N.Y.H., Xia, H.H.X., Huang, J.Q., Chan, A.O.O., Lam, S.K. & Wong, B.C.Y. A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro-oesophageal reflux disease in the Chinese population, 1407
 Wong, W.M., Lam, S.K., Lai, K.C., Chu, K.M., Xia, H.H.X., Wong, K.W., Cheung, K.L., Lin, S.K. & Wong, B.C.Y. A rapid-release 50-mg tablet-based ¹³C-urea breath test for the diagnosis of *Helicobacter pylori* infection, 253
 Woodcock, B.G. *see* Alsalamah, S.
 work productivity, 1309
 Wray, H. *see* Wilding, I.R.
 Wruble, L.D. *see* Sandborn, W.J.
 Wu, J.-J. *see* Sheu, B.-S.
 xerostomia, 217
 Xia, H.H.X. *see* Wong, W.M.

- Xia, H.H.X., Lai, K.C., Lam, S.K., Hu, W.H.C., Wong, N.Y.H., Hui, W.M., Lau, C.P., Chen, W.H., Chan, C.K., Wong, W.M. & Wong, B.C.Y. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain, 369
- Xia, H.H.-X., Talley, N.J., Blum, A.L., O'Morain, C.A., Stolte, M., Bolling-Sternevald, E. & Mitchell, H.M. Clinical and pathological implications of IgG antibody responses to *Helicobacter pylori* and its virulence factors in non-ulcer dyspepsia, 935
- Yamaoka, Y. *see* Graham, D.Y.
- Yang, H.-B. *see* Sheu, B.-S.
- Yarmohammadi, H. *see* Kaviani, M.J.
- Yee, Y.K. *see* Wong, W.M.
- Yoshihara, M. *see* Sasaki, A.
- You, J.H.S., Lee, A.C.M., Wong, S.C.Y. & Chan, F.K.L. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis, 785
- Yu, C. *see* Hunt, R.H.
- Yuen, M.-F. *see* Hui, C.-K.
- Yuen, M.F. *see* Wong, W.M.
- Zafrani, E.-S. *see* Hézode, C.
- Zagari, R.M. *see* Perri, F.
- Zelmac, 577
- Zentilin, P., Dulbecco, P., Bilardi, C., Gambaro, C., Iiritano, E., Biagini, R., Mela, G.S., Tessieri, L., Mele, M.R., Mansi, C., Pandolfo, N., Vigneri, S. & Savarino, V. Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD), 353
- Zentilin, P., Iiritano, E., Vignale, C., Bilardi, C., Mele, M.R., Spaggiari, P., Gambaro, C., Dulbecco, P., Tessieri, L., Reglioni, S., Mansi, C., Mastracci, L., Vigneri, S., Fiocca, R. & Savarino, V. *Helicobacter pylori* infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease, 1057
- Zinsmeister, A.R. *see* Kalantar, J.S.
- Zinsmeister, A.R. *see* Kim, H.J.
- Zipprich, A., Meiss, F., Steudel, N., Szegoleit, U., Fleig, W.E. & Kleber, G. ¹³C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply, 1559
- Zullo, A., Vaira, D., Vakil, N., Hassan, C., Gatta, L., Ricci, C., De Francesco, V., Menegatti, M., Tampieri, A., Perna, F., Rinaldi, V., Perri, F., Papadia, C., Fornari, F., Pilati, S., Mete, L.S., Merla, A., Poti, R., Marinone, G., Savioli, A., Campo, S.M.A., Faleo, D., Ierardi, E., Miglioli, M. & Morini, S. High eradication rates of *Helicobacter pylori* with a new sequential treatment, 719

1000

1000

